Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

OBJECTIVE--To compare the efficacy, tolerance and safety of 50-150 micrograms orally administered iloprost given twice a day versus placebo in patients with Raynaud's syndrome. METHODS--The study was multicentre (n = 3), double blind and placebo controlled. Sixty three patients who had eight or more...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Ann Rheum Dis
Principais autores:	Belch, J J, Capell, H A, Cooke, E D, Kirby, J D, Lau, C S, Madhok, R, Murphy, E, Steinberg, M
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 1995
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC1005556/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7538285/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/ard.54.3.197
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!